Professional Documents
Culture Documents
Bladder Cancer ESMO 2014
Bladder Cancer ESMO 2014
doi:10.1093/annonc/mdu223
Published online 5 August 2014
incidence and epidemiology and adenocarcinomas [4]. This guideline relates to transitional
cell carcinoma.
In Europe, an estimated 151 297 new cases of bladder cancer
were diagnosed in 2012, with an age-standardised incidence rate
( per 100 000 persons) of 17.7 for males and 3.5 for females.
staging and risk assessment
Overall, the annual crude incidence rate is 20.4/100 000. In A complete history and physical examination should be under-
2012, there were 52 395 deaths from bladder cancer with an taken, together with laboratory tests evaluating full blood counts
clinical practice
annual crude mortality rate of 7.1/100 000 [1]. Approximately and renal function. Bladder ultrasonography most frequently
guidelines
70% of patients with bladder cancer are >65 years of age. gives an initial suspicious image, but final diagnosis of bladder
The most common presenting symptom is painless haema- cancer is based on cystoscopy and evaluation of the resected
turia, seen in >80% of patients. Others may also present with tissue. Cystoscopic examination and TURBT under anaesthesia
irritative symptoms such as dysuria, frequency or urgency. should be carried out following a standardised protocol
Symptoms of metastases such as bone or flank pain are rare. (Figure 1). Complete resection of all tumour tissue should be
Most diagnosed cases of muscle-invasive bladder cancer (MIBC; achieved when possible. At the time of TURBT, the number of
80%–90%) present as primary invasive bladder cancer. However, tumours, their size(s) and the presence of extra-vesical extension
up to 15% of patients have a history of non-muscle-invasive or invasion of adjacent organs by bimanual examination should
bladder cancer (NMIBC), mainly high-risk cases. be documented. Ideally, both the base of the tumour and the
tumour edges should be sent separately to the pathologist to
pathological diagnosis ensure the presence of lamina propria and bladder muscle in the
specimen, essential for accurate staging.
Pathological diagnosis should be made according to the World Because associated carcinoma in situ (CIS) has been shown to
Health Organisation (WHO) classification (Table 1) from a be an adverse prognostic factor, bladder biopsies should be taken
biopsy obtained during transurethral resection of the bladder from reddish, suspicious areas when present or random biopsies
tumour (TURBT). Tumours should be graded as high and low from normal looking urothelium if there is a positive cytology or
grade according to the latest WHO criteria and can concomi- a previous diagnosis of associated CIS. Similarly, biopsies from
tantly be graded according to the 1973 classifications of high, the prostatic urethra should be taken if the tumour is located at
low and intermediate grade carcinoma [3]. Ninety percent of the trigone or bladder neck area, or when there is no bladder
bladder carcinomas are transitional cell carcinomas. The other tumour and the procedure is carried out to study a positive cy-
types of urothelial cancer are relatively uncommon, including tology, since the tumour could be located in the urothelium
lymphoepithelioma-like or sarcomatoid carcinomas, micropapil- lining the prostatic urethra or the ducts [III, C] [6]. Management
lary or nested variants and primary squamous cell carcinomas of bladder cancer is based on the pathological findings of the
biopsy, with attention to histology, grade and depth of invasion.
MIBC should be staged according to the tumour–node–metasta-
*Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei
sis (TNM) system and grouped into categories (Table 2).
4, CH-6962 Viganello-Lugano, Switzerland. Once histology confirms muscle invasion, local staging can be
E-mail: clinicalguidelines@esmo.org carried out with further imaging studies such as computed tom-
† ography (CT) or magnetic resonance imaging. Either test can
Approved by the ESMO Guidelines Working Group: February 2011, last update June
2014. This publication supersedes the previously published version—Ann Oncol 2011; be used to assess extra-vesical invasion but these tests are often
22 (Suppl 6): vi45–vi49. unable to reliably differentiate T2 from T3a, T3b or even T4a.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
Annals of Oncology clinical practice guidelines
Importantly, because of interference by post-TURBT peri- management of local/locoregional
vesical reactions, imaging is recommended before TURBT, if disease
possible, when an invasive tumour is suspected (by ultrasound
or cystoscopy). Similarly, both tests are useful to detect enlarged treatment of non-muscle-invasive bladder cancer
nodes—over 8 mm in the pelvic area and over 1 cm for abdom- Complete TURBT is the treatment of choice for any initial
inal nodes—and distant metastasis. Hydronephrosis should also bladder tumour [9], followed by instillations according to risk
be taken into account as it has been shown to be an independent stratification in NMIBC [I, A]. A second TURBT is a reasonable
predictor of advanced stage bladder cancer and poor clinical option in high-risk NMIBC tumours, either before intravesical
outcome, and it predicts extra-vesical disease and node-positive therapy [II, B] or thereafter [III, B]. Presentations with very
disease [8]. A chest CT should be carried out at the same time as high-risk features, e.g. multiple grade 3 T1 tumours with TIS or
the abdomino-pelvis CT. Because a synchronous upper tract increased depth of invasion, may be considered for cystectomy.
Risk factors:
0.8 0 = KPS > 80, no visceral mets
1 = KPS < 80, or visceral mets
2 = KPS < 80, and visceral mets
Proportion surviving
0.6
Figure 1. Prognostic factors in first-line advanced disease. Reprinted from [5] with permission of © 1999 American Society of Clinical Oncology. All rights reserved .
ECOG-PS ≥1
0.25
Figure 2. Prognostic factors in second line. Reprinted from [34] with permission of © 2010 American Society of Clinical Oncology. All rights reserved.
Presentation
1. Painless haematuria (80% of patients)
2. Irritative symptoms (e.g. dysuria, frequency, urgency) (invasive or high grade tumours)
3. Bone pain (advanced metastatic cases) or flank pain (from retroperitoneal metastases or ureteral obstruction)
Workup
1. History and physical examination
2. Cystoscopic evaluation including biopsy by transurethral resection (TUR) with bimanual examination
Radical Cystectomy
with
Lymphadenectomy
Contemplate 2nd
TURBT if:
incomplete initial
TUR, no muscle
present in
specimen or Further Adjuvant Adjuvant
high-risk NMIBC Chemotherapy Chemotherapy
(limited data) (if no neoadjuvant)
Figure 3. Overview of clinical management of patient with suspected bladder cancer (local disease, organ preservation therapy, and metastatic disease).
Combined Radiotherapy
Combined
chemoradiotherapy alone
chemoradiotherapy
Total dose 55-64 Gy
40 Gy
Salvage
cystectomy if
persisting Complete
tumour Radiotherapy if
complete
response (CR)
Surveillance
Cystoscopic evaluation (3 months)
with TUR bladder biopsy
(every 6 months)
Clinical trial
Fig. 3 Continued
bladder cancer treated with bacillus Calmette-Guérin: external validation of the 42. Taylor BS, Barretina J, Socci ND et al. Functional copy-number alterations in
EORTC risk tables. Eur Urol 2011; 60: 423–430. cancer. PLoS One 2008; 3: e3179.
38. Xylinas E, Kent M, Kluth L et al. Accuracy of the EORTC risk tables and of the 43. Gui Y, Guo G, Huang Y et al. Frequent mutations of chromatin remodeling genes in
CUETO scoring model to predict outcomes in non-muscle-invasive urothelial transitional cell carcinoma of the bladder. Nat Genet 2011; 43: 875–878.
carcinoma of the bladder. Br J Cancer 2013; 109: 1460–1466. 44. Solomon DA, Kim JS, Bondaruk J et al. Frequent truncating mutations of STAG2 in
39. Fernandez-Gomez J, Madero R, Solsona E et al. Predicting nonmuscle invasive bladder cancer. Nat Genet 2013; 45: 1428–1430.
bladder cancer recurrence and progression in patients treated with bacillus 45. Iyer G, Hanrahan AJ, Milowsky MI et al. Genome sequencing identifies a basis for
Calmette-Guérin: the CUETO scoring model. J Urol 2009; 182: 2195–2203. everolimus sensitivity. Science 2012; 338: 221.
40. Iyer G, Al-Ahmadie H, Schultz N et al. Prevalence and co-occurrence of actionable 46. Ross JS, Wang K, Al-Rohil RN et al. Advanced urothelial carcinoma: next-
genomic alterations in high-grade bladder cancer. J Clin Oncol 2013; 31: generation sequencing reveals diverse genomic alterations and targets of therapy.
3133–3140. Mod Pathol 2014; 27: 271–280.
41. Al-Ahmadie HA, Iyer G, Janakiraman M et al. Somatic mutation of fibroblast growth 47. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections